Loading...

Bakhu Holdings

OTCPK:BKUH
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BKUH
OTCPK
$1B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Bakhu Holdings, Corp. does not have significant operations. The last earnings update was 2 days ago. More info.


Add to Portfolio Compare Print
BKUH Share Price and Events
7 Day Returns
0%
OTCPK:BKUH
-0.5%
US Pharmaceuticals
0.5%
US Market
1 Year Returns
-10%
OTCPK:BKUH
6%
US Pharmaceuticals
0.8%
US Market
BKUH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Bakhu Holdings (BKUH) 0% -10% - -10% 971.4% 2150%
US Pharmaceuticals -0.5% 0.9% -2.7% 6% 9.1% 14%
US Market 0.5% 0.2% 1.1% 0.8% 37.4% 37.5%
1 Year Return vs Industry and Market
  • BKUH underperformed the Pharmaceuticals industry which returned 6% over the past year.
  • BKUH underperformed the Market in United States of America which returned 0.8% over the past year.
Price Volatility
BKUH
Industry
5yr Volatility vs Market

BKUH Value

 Is Bakhu Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Bakhu Holdings is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Bakhu Holdings has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Bakhu Holdings. This is due to cash flow or dividend data being unavailable. The share price is $4.5.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Bakhu Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Bakhu Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:BKUH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-04-30) in USD $-0.13
OTCPK:BKUH Share Price ** OTCPK (2019-06-14) in USD $4.5
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 17.22x
United States of America Market PE Ratio Median Figure of 3,091 Publicly-Listed Companies 17.68x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Bakhu Holdings.

OTCPK:BKUH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:BKUH Share Price ÷ EPS (both in USD)

= 4.5 ÷ -0.13

-33.71x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bakhu Holdings is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Bakhu Holdings is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Bakhu Holdings's expected growth come at a high price?
Raw Data
OTCPK:BKUH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -33.71x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.55x
United States of America Market PEG Ratio Median Figure of 2,125 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Bakhu Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Bakhu Holdings's assets?
Raw Data
OTCPK:BKUH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-04-30) in USD $0.00
OTCPK:BKUH Share Price * OTCPK (2019-06-14) in USD $4.5
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 183 Publicly-Listed Pharmaceuticals Companies 3.16x
United States of America Market PB Ratio Median Figure of 5,244 Publicly-Listed Companies 1.79x
OTCPK:BKUH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:BKUH Share Price ÷ Book Value per Share (both in USD)

= 4.5 ÷ 0.00

-9868.42x

* Primary Listing of Bakhu Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bakhu Holdings has negative assets, we can't compare the value of its assets to the US Pharmaceuticals industry average.

Next steps:

  1. Take a look at our analysis of BKUH’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Show me more potentially undervalued companies in the Pharmaceuticals industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Bakhu Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Bakhu Holdings has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

BKUH Future Performance

 How is Bakhu Holdings expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bakhu Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
14.7%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Bakhu Holdings expected to grow at an attractive rate?
  • Unable to compare Bakhu Holdings's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Bakhu Holdings's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Bakhu Holdings's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:BKUH Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 14.7%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:BKUH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:BKUH Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-04-30 0 -14
2019-01-31 0 -4
2018-10-31 0 -4
2018-07-31 0 -4
2018-04-30 0 0
2018-01-31 0 0
2017-10-31 0 0
2017-07-31 0 0
2016-07-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Bakhu Holdings is high growth as no earnings estimate data is available.
  • Unable to determine if Bakhu Holdings is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:BKUH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Bakhu Holdings Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:BKUH Past Financials Data
Date (Data in USD Millions) EPS *
2019-04-30 -0.13
2019-01-31 -0.09
2018-10-31 -0.14
2018-07-31 -0.41
2018-04-30 -1.03
2018-01-31 -0.60
2017-10-31 -0.51
2017-07-31 -0.22
2016-07-31 -0.13

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Bakhu Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of BKUH’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Bakhu Holdings's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Bakhu Holdings's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Bakhu Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Bakhu Holdings has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

BKUH Past Performance

  How has Bakhu Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Bakhu Holdings's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Bakhu Holdings does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Bakhu Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Bakhu Holdings's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Bakhu Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Bakhu Holdings Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:BKUH Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-04-30 -14.25 14.23
2019-01-31 -3.84 3.82
2018-10-31 -3.87 3.84
2018-07-31 -3.83 3.80
2018-04-30 -0.23 0.22
2018-01-31 -0.16 0.15
2017-10-31 -0.13 0.13
2017-07-31 -0.06 0.06
2016-07-31 -0.03 0.03

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Bakhu Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Bakhu Holdings has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Bakhu Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Bakhu Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Bakhu Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

BKUH Health

 How is Bakhu Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Bakhu Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Bakhu Holdings's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Bakhu Holdings has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Bakhu Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Bakhu Holdings has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Bakhu Holdings Company Filings, last reported 1 month ago.

OTCPK:BKUH Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-04-30 -0.13 0.13 0.00
2019-01-31 -0.13 0.13
2018-10-31 -0.13 0.13
2018-07-31 -0.01 0.01 0.01
2018-04-30 -0.30 0.06 0.00
2018-01-31 -0.20 0.05 0.00
2017-10-31 -0.17 0.04 0.01
2017-07-31 -0.09 0.02 0.00
2016-07-31 -0.03 0.01
  • Bakhu Holdings has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Bakhu Holdings's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Bakhu Holdings has less than a year of cash runway based on current free cash flow.
  • Bakhu Holdings has less than a year of cash runway if free cash flow continues to grow at historical rates of 104.4% each year.
X
Financial health checks
We assess Bakhu Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Bakhu Holdings has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

BKUH Dividends

 What is Bakhu Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Bakhu Holdings dividends.
If you bought $2,000 of Bakhu Holdings shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Bakhu Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Bakhu Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:BKUH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.7%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Bakhu Holdings has not reported any payouts.
  • Unable to verify if Bakhu Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Bakhu Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Bakhu Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Bakhu Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Bakhu Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Bakhu Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

BKUH Management

 What is the CEO of Bakhu Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tom Emmitt
COMPENSATION $0
AGE 55
TENURE AS CEO 1.1 years
CEO Bio

Mr. Thomas K. Emmitt, also known as Tom, has been Chief Executive Officer and Director at Bakhu Holdings, Corp since May 15, 2018 and serves as its Chairman. Mr. Emmitt serves as Principal Accounting and Financial Officer and Secretary of Bakhu Holdings, Corp. Mr. Emmitt is the Founder and President of The Law Office of Tom Emmitt, a law firm specializing in civil litigation since June, 2000. Mr. Emmitt has successfully prosecuted over 400 civil cases in the areas of personal injury and employment law. From March, 2009 through January, 2016, Mr. Emmitt was in-house counsel to Green Medica Holdings Corporation, a nutraceutical company specializing in mushroom derivatives and DHA/GPC products. Beginning in January, 2016, and continuing through the present, Mr. Emmitt has been in-house counsel to the Oz Corporation, a management consulting company providing services to small and mid-cap companies, and overseeing processes, strategic planning, startup funding and recruitment of management executives. Finally, Mr. Emmitt has been the President of Belltower Entertainment Corp. (BTOW), a publicly traded entity since December, 2017. Mr. Emmitt is experienced in all phases of financial analysis, information technology and marketing. Mr. Emmitt is a graduate of Ventura College, and the West Los Angeles School of Law.

CEO Compensation
  • Insufficient data for Tom to compare compensation growth.
  • Tom's remuneration is lower than average for companies of similar size in United States of America.
Management Team

Tom Emmitt

TITLE
Chairman
AGE
55
TENURE
1.1 yrs
Board of Directors

Tom Emmitt

TITLE
Chairman
AGE
55
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Bakhu Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Bakhu Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

BKUH News

Simply Wall St News

BKUH Company Info

Description

Bakhu Holdings, Corp. does not have significant operations. It intends to acquire cell extraction related licenses for application in the medical and wellness fields. The company was formerly known as Planet Resources, Corp. and changed its name to Bakhu Holdings, Corp. in May 2009. Bakhu Holdings, Corp. was founded in 2008 and is based in Harbor City, California.

Details
Name: Bakhu Holdings, Corp.
BKUH
Exchange: OTCPK
Founded: 2008
$1,300,221,828
288,938,184
Website: http://www.bakhuholdings.com
Address: Bakhu Holdings, Corp.
24328 Vermont Avenue,
Suite 300,
Harbor City,
California, 90710,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK BKUH Common Stock Pink Sheets LLC US USD 23. Jun 2009
Number of employees
Current staff
Staff numbers
3
Bakhu Holdings employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/16 00:15
End of day share price update: 2019/06/14 00:00
Last earnings filing: 2019/06/14
Last earnings reported: 2019/04/30
Last annual earnings reported: 2018/07/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.